NCT02404870View on ClinicalTrials.gov

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2014

Primary Completion Date

May 1, 2019

Study Completion Date

September 3, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

Placebo

DRUG

Canagliflozin

Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02404870 - Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers | Biotech Hunter | Biotech Hunter